Clinical Trial Results: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ATG-010 with bortezomib and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• ATG-010
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Antengene Corporation | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2026-08-10